Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice.
J Clin Lipidol
; 17(3): 412-414, 2023.
Article
en En
| MEDLINE
| ID: mdl-37029056
ABSTRACT
Nearly two-thirds of individuals with atherosclerotic cardiovascular disease (ASCVD) do not reach target low-density lipoprotein cholesterol despite statin therapy. Three novel lipid-lowering therapies have proven to further reduce ASCVD beyond statins, including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), and icosapent ethyl. This study evaluated the use of these three agents in 728,423 individuals with ASCVD from 89 US health systems from 01/2018 through 03/2021 using the electronic health record. As of 2021, only 6.0% of ASCVD patients were on ezetimibe, 1.6% were on a PCSK9i, and 1.3% on icosapent ethyl, with utilization only marginally increasing over the study period. Addressing the underutilization of non-statin lipid-lowering therapy for secondary prevention is a critical step in improving the treatment gap of patients with residual risk of ASCVD.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
Problema de salud:
1_doencas_nao_transmissiveis
/
1_sistemas_informacao_saude
/
2_muertes_prematuras_enfermedades_notrasmisibles
Asunto principal:
Enfermedades Cardiovasculares
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Aterosclerosis
/
Anticolesterolemiantes
Límite:
Humans
Idioma:
En
Revista:
J Clin Lipidol
Asunto de la revista:
BIOQUIMICA
/
METABOLISMO
Año:
2023
Tipo del documento:
Article